Roberto Salvatori

List of Publications by Year
in descending order

200	6,604	87888 38	85541 71
papers	citations	h-index	g-index

202	202	202	4591
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Speed of response to dopaminergic agents in prolactinomas. Endocrine, 2022, 75, 883-888.	2.3	2
2	Dental arches in inherited severe isolated growth hormone deficiency. Growth Hormone and IGF Research, 2022, 62, 101444.	1.1	4
3	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. Pituitary, 2022, 25, 420-432.	2.9	7
4	Art and science: impact of semioccluded vocal tract exercises and choral singing on quality of life in subjects with congenital GH deficiency. Archives of Endocrinology and Metabolism, 2022, , .	0.6	0
5	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. Frontiers in Oncology, 2022, 12, 798517.	2.8	9
6	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. Frontiers in Endocrinology, 2022, 13, 840971.	3.5	2
7	The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions. Expert Review of Endocrinology and Metabolism, 2022, , 1-20.	2.4	1
8	Growth of teeth and bones in adult subjects with congenital untreated isolated growth hormone deficiency. Growth Hormone and IGF Research, 2022, , 101469.	1.1	4
9	Formant Frequencies, Cephalometric Measures, and Pharyngeal Airway Width in Adults With Congenital, Isolated, and Untreated Growth Hormone Deficiency. Journal of Voice, 2021, 35, 61-68.	1.5	7
10	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e917-e925.	3.6	37
11	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushingâ€™s syndrome. Pituitary, 2021, 24, 104-115.	2.9	20
12	Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 81-89.	5.7	23
13	Preoperative BMI Predicts Postoperative Weight Gain in Adult-onset Craniopharyngioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1603-1617.	3.6	8
14	Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1953-e1967.	3.6	24
15	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
16	Reduced fibroblast growth factor 21 and Î²-Klotho secretion in untreated congenital isolated GH deficiency. Endocrine, 2021, 73, 160-165.	2.3	1
17	Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls. Endocrine, 2021, 72, 349-355.	2.3	6
18	Response to Letter to the Editor From Lukas Andereggen: â€œPitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Reviewâ€• Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3291-e3292.	3.6	0

#	Article	IF	Citations
19	Circulating microRNA profile in humans and mice with congenital GH deficiency. Aging Cell, 2021, 20, e13420.	6.7	9
20	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. Expert Review of Endocrinology and Metabolism, 2021, 16, 159-174.	2.4	8
21	Advances in differential diagnosis and management of growth hormone deficiency in children. Nature Reviews Endocrinology, 2021, 17, 608-624.	9.6	31
22	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology, 2021, 185, 525-538.	3.7	32
23	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
24	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	3.6	207
25	Acromegaly in the setting of Tatton-Brown-Rahman Syndrome. Pituitary, 2020, 23, 167-170.	2.9	5
26	Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. Pharmacological Research, 2020, 152, 104614.	7.1	9
27	Vestibular function in severe GH deficiency due to an inactivating mutation in the GH-releasing hormone receptor gene. Endocrine, 2020, 67, 659-664.	2.3	3
28	Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency. Endocrine, 2020, 70, 388-395.	2.3	4
29	The 5-factor modified frailty index predicts health burden following surgery for pituitary adenomas. Pituitary, 2020, 23, 630-640.	2.9	36
30	Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4558-e4566.	3.6	14
31	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
32	Long-acting pasireotide improves clinical signs and quality of life in Cushingâ€™s disease: results from a phase III study. Journal of Endocrinological Investigation, 2020, 43, 1613-1622.	3.3	16
33	Perioperative Glucocorticoid Therapy in Adrenal Insufficiency: What Is the Correct Dose?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2078-e2079.	3.6	2
34	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. European Journal of Endocrinology, 2020, 183, 453-462.	3.7	18
35	MON-276 Post-Surgical Metabolic Outcomes in Adult-Onset Craniopharyngioma: A Single Pituitary Center Experience. Journal of the Endocrine Society, 2020, 4, .	0.2	0
36	SUN-117 Growth Hormone-Releasing Hormone (GHRH) Deficiency Promotes Inflammation Associated Carcinogenesis. Journal of the Endocrine Society, 2020, 4, .	0.2	0

#	Article	IF	Citations
37	Increased pain and inflammatory sensitivity in growth hormone-releasing hormone (GHRH) knockout mice. Prostaglandins and Other Lipid Mediators, 2019, 144, 106362.	1.9	10
38	Sweat and vitamin D status in congenital, lifetime, untreated GH deficiency. Endocrine, 2019, 65, 710-713.	2.3	7
39	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 855-865.	11.4	60
40	Macrophages From Subjects With Isolated GH/IGF-I Deficiency Due to a GHRH Receptor Gene Mutation Are Less Prone to Infection by Leishmania amazonensis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 311.	3.9	10
41	Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes. Frontiers in Oncology, 2019, 8, 660.	2.8	4
42	Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to a GHRH Receptor Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2777-2784.	3.6	8
43	Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease. Expert Review of Endocrinology and Metabolism, 2019, 14, 167-178.	2.4	8
44	Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure. Abdominal Radiology, 2019, 44, 1152-1154.	2.1	1
45	Adult individuals with congenital, untreated, severe isolated growth hormone deficiency have satisfactory muscular function. Endocrine, 2019, 63, 112-119.	2.3	17
46	Effects of Therapy With Semi-occluded Vocal Tract and Choir Training on Voice in Adult Individuals With Congenital, Isolated, Untreated Growth Hormone Deficiency. Journal of Voice, 2019, 33, 808.e1-808.e5.	1.5	9
47	Walking and postural balance in adults with severe short stature due to isolated GH deficiency. Endocrine Connections, 2019, 8, 416-424.	1.9	5
48	Cytopathological Analysis in the Diagnosis of Corticotroph Adenomas: Technical Note. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.8	0
49	MON-419 Sellar Plasmacytoma: A Commonly Misdiagnosed Sellar Mass. Journal of the Endocrine Society, 2019, 3, .	0.2	0
50	MON-437 Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to GHRH Receptor Gene Mutation. Journal of the Endocrine Society, 2019, 3, .	0.2	0
51	SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience. Journal of the Endocrine Society, 2019, 3, .	0.2	0
52	Posterior pituitary abnormalities caused by pituitary tumors. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 25-28.	1.4	1
53	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	11.4	116
54	Comparative Cost Analysis of Endoscopic versus Microscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 131-138.	0.8	12

#	Article	IF	Citations
55	Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine, 2018, 59, 4-6.	2.3	4
56	Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against Streptococcus pneumoniae. Frontiers in Immunology, 2018, 9, 2175.	4.8	13
57	Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine, 2018, 61, 105-117.	2.3	5
58	Immunological and microbiological periodontal profiles in isolated growth hormone deficiency. Journal of Periodontology, 2018, 89, 1351-1361.	3.4	4
59	Behavioural phenotyping, learning and memory in young and aged growth hormone-releasing hormone-knockout mice. Endocrine Connections, 2018, 7, 924-931.	1.9	17
60	Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Frontiers in Endocrinology, 2018, 9, 78.	3.5	18
61	The Severe Deficiency of the Somatotrope GH-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor 1 Axis of Ghrhâ^'/â^' Mice Is Associated With an Important Splenic Atrophy and Relative B Lymphopenia. Frontiers in Endocrinology, 2018, 9, 296.	3.5	21
62	Occurrence of neoplasms in individuals with congenital, severe GH deficiency from the Itabaianinha kindred. Growth Hormone and IGF Research, 2018, 41, 71-74.	1.1	11
63	MECHANISMS IN ENDOCRINOLOGY: The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. European Journal of Endocrinology, 2017, 177, R85-R97.	3.7	51
64	Altered sleep patterns in patients with non-functional GHRH receptor. European Journal of Endocrinology, 2017, 177, 51-57.	3.7	11
65	Ocular findings in adult subjects with an inactivating mutation in GH releasing hormone receptor gene. Growth Hormone and IGF Research, 2017, 34, 8-12.	1.1	9
66	Current best practice in the management of patients after pituitary surgery. Therapeutic Advances in Endocrinology and Metabolism, 2017, 8, 33-48.	3.2	88
67	The Somatotrope Growth Hormone-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor-1 Axis in Immunoregulation and Immunosenescence. Frontiers of Hormone Research, 2017, 48, 147-159.	1.0	22
68	Walter E. Dandy: his contributions to pituitary surgery in the context of the overall Johns Hopkins Hospital experience. Pituitary, 2017, 20, 683-691.	2.9	7
69	Effects of growth hormone-releasing hormone gene targeted ablation on ghrelin-induced feeding. Growth Hormone and IGF Research, 2017, 37, 40-46.	1.1	12
70	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	3.7	12
71	Endoscopic Versus Microscopic Transsphenoidal Approach for Pituitary Adenomas: Comparison of Outcomes During the Transition of Methods of a Single Surgeon. World Neurosurgery, 2017, 97, 317-325.	1.3	36
72	Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary, 2017, 20, 109-115.	2.9	44

#	Article	IF	Citations
73	Posttreatment Management of Cushingâ€™s Disease. , 2017, , 135-167.		0
74	A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary, 2017, 20, 605-618.	2.9	10
75	The Perioperative and Postoperative Care for Pituitary Patients. , 2017, , 59-69.		0
76	Venous Sampling for Cushing Disease: Comparison of Internal Jugular Vein and Inferior Petrosal Sinus Sampling. Endocrine Practice, 2016, 22, 1057-1061.	2.1	9
77	Brazilian adult individuals with untreated isolated GH deficiency do not have accelerated subclinical atherosclerosis. Endocrine Connections, 2016, 5, 41-46.	1.9	19
78	Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. Journal of Endocrinological Investigation, 2016, 39, 1277-1284.	3.3	8
79	Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert Opinion on Therapeutic Targets, 2016, 20, 1259-1265.	3.4	25
80	Pituitary abscess with unusual MRI appearance. Endocrine, 2016, 54, 837-838.	2.3	5
81	Abnormal vascular and neural retinal morphology in congenital lifetime isolated growth hormone deficiency. Growth Hormone and IGF Research, 2016, 30-31, 11-15.	1.1	12
82	Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency. Endocrine, 2016, 54, 182-190.	2.3	24
83	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3888-3921.	3.6	601
84	Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. Journal of Oncology Pharmacy Practice, 2016, 22, 517-522.	0.9	11
85	Voice Formants in Individuals With Congenital, Isolated, Lifetime Growth Hormone Deficiency. Journal of Voice, 2016, 30, 281-286.	1.5	18
86	CT Appearance of Adrenal Cystic Lymphangioma: Radiologic-Pathologic Correlation. American Journal of Roentgenology, 2016, 206, 81-85.	2.2	13
87	Subjects with isolated GH deficiency due to a null GHRHR mutation eat proportionally more, but healthier than controls. Endocrine, 2016, 51, 317-322.	2.3	14
88	The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone. Blood, 2016, 128, 5640-5640.	1.4	0
89	Letter to the Editor: Comment on â€œEffect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Studyâ€•by Kratz E., et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L107-L107.	3.6	0
90	Increased locomotor and thermogenic activity in mice with targeted ablation of the GHRH gene. Growth Hormone and IGF Research, 2015, 25, 80-84.	1.1	25

#	Article	IF	Citations
91	Growth hormone deficiency in patients with obesity. Endocrine, 2015, 49, 304-306.	2.3	11
92	Perioperative Corticosteroid Management for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 221-228.	1.9	13
93	Discovery of Cushingâ€™s Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. Obesity Surgery, 2015, 25, 2306-2313.	2.1	12
94	Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects. Journal of Human Genetics, 2015, 60, 335-338.	2.3	4
95	Bladder pheochromocytoma. Endocrine, 2015, 48, 349-350.	2.3	2
96	Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes and Endocrinology,the, 2015, 3, 132-140.	11.4	15
97	Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification. Endocrine, 2014, 47, 191-7.	2.3	12
98	Synchronous GH- and prolactin-secreting pituitary adenomas. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140052.	0.5	2
99	Hearing Status in Adult Individuals with Lifetime, Untreated Isolated Growth Hormone Deficiency. Otolaryngology - Head and Neck Surgery, 2014, 150, 464-471.	1.9	20
100	Increased Visceral Adiposity and Cortisol to Cortisone Ratio in Adults With Congenital Lifetime Isolated GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3285-3289.	3.6	28
101	Liver status in congenital, untreated, isolated GH deficiency. Endocrine Connections, 2014, 3, 132-137.	1.9	9
102	Clinical features of sellar and suprasellar meningiomas. Pituitary, 2014, 17, 342-348.	2.9	43
103	Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary, 2014, 17, 13-21.	2.9	44
104	Lingual thyroid. Endocrine, 2014, 46, 355-356.	2.3	1
105	Growth Hormone Should Be Used Only for Approved Indications. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 409-411.	3.6	22
106	Detection of Pituitary Antibodies by Immunofluorescence: Approach and Results in Patients With Pituitary Diseases. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1758-1766.	3.6	66
107	Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary, 2014, 17, 451-456.	2.9	28
108	Behavioural phenotyping of male growth hormone-releasing hormone (GHRH) knockout mice. Growth Hormone and IGF Research, 2014, 24, 192-197.	1.1	23

#	Article	IF	Citations
109	Surgical treatment of microprolactinomas: pros. Endocrine, 2014, 47, 725-729.	2.3	29
110	A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140048.	0.5	6
111	Prolactin and sex steroids levels in congenital lifetime isolated GH deficiency. Endocrine, 2013, 44, 207-211.	2.3	9
112	Isolated GH Deficiency due to a GHRH Receptor Mutation Causes Hip Joint Problems and Genu Valgum, and Reduces Size but not Density of Trabecular and Mixed Bone. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1710-E1715.	3.6	21
113	Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1361-1375.	3.6	358
114	Molecular and Clinical Aspects of GHRH Receptor Mutations. Endocrine Development, 2013, 24, 106-117.	1.3	19
115	Effects of isolated GH deficiency on adipose tissue, feeding and adipokines in mice. Growth Hormone and IGF Research, 2013, 23, 237-242.	1.1	17
116	Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocrine Connections, 2013, 2, 112-117.	1.9	16
117	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. European Journal of Endocrinology, 2013, 169, R153-R164.	3.7	102
118	Arrest of atherosclerosis progression after interruption of GH replacement in adults with congenital isolated GH deficiency. European Journal of Endocrinology, 2012, 166, 977-982.	3.7	7
119	Insulin Sensitivity and Î²-Cell Function in Adults with Lifetime, Untreated Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1013-1019.	3.6	42
120	Pituitary Antibodies in Women with Hashimoto's Thyroiditis: Prevalence in Diagnostic and Prediagnostic Sera. Thyroid, 2012, 22, 509-515.	4.5	6
121	Cushing Syndrome: Maybe Not So Uncommon of an Endocrine Disease. Journal of the American Board of Family Medicine, 2012, 25, 199-208.	1.5	72
122	A Lifelong Smoker with Hypopituitarism: Rethinking the Hypothesis of a Tumor in the Hypophysis. Case Reports in Medicine, 2012, 2012, 1-4.	0.7	1
123	The consequences of growth hormoneâ€releasing hormone receptor haploinsufficiency for bone quality and insulin resistance. Clinical Endocrinology, 2012, 77, 379-384.	2.4	3
124	Management Options for Persistent Postoperative Acromegaly. Neurosurgery Clinics of North America, 2012, 23, 621-638.	1.7	10
125	Prevalence of antipituitary antibodies in acromegaly. Pituitary, 2012, 15, 490-494.	2.9	11
126	ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity. Pituitary, 2012, 15, 526-532.	2.9	22

#	Article	IF	Citations
127	<scp>ACTH</scp>â€secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clinical Endocrinology, 2012, 77, 871-876.	2.4	27
128	Voice Quality in Short Stature With and Without GH Deficiency. Journal of Voice, 2012, 26, 673.e13-673.e19.	1.5	20
129	Neuroendocrine Growth Disorders â€“ Dwarfism, Gigantism. , 2012, , 707-721.		0
130	Medical Management of Hormone-Secreting Pituitary Tumors. , 2012, , 203-214.		0
131	Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. Pituitary, 2012, 15, 61-67.	2.9	19
132	Lifetime Growth Hormone (GH) Deficiency: Impact on Growth, Metabolism, Body Composition, and Survival Capacity. , 2012, , 2699-2710.		4
133	Effects of depot growth hormone replacement on thyroid function and volume in adults with congenital isolated growth hormone deficiency. Journal of Endocrinological Investigation, 2012, 35, 265-8.	3.3	4
134	Effects of GH deficiency and GH replacement on inter-male aggressiveness in mice. Growth Hormone and IGF Research, 2011, 21, 76-80.	1.1	13
135	Familial Isolated Pituitary Adenomas: From Genetics to Therapy. Clinical and Translational Science, 2011, 4, 55-62.	3.1	19
136	Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary, 2011, 14, 68-74.	2.9	67
137	A Novel Frame Shift Mutation in the GHRH Receptor Gene in Familial Isolated GH Deficiency: Early Occurrence of Anterior Pituitary Hypoplasia. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2982-2986.	3.6	21
138	GH, But Not GHRH, Plays a Role in the Development of Experimental Autoimmune Encephalomyelitis. Endocrinology, 2011, 152, 3803-3810.	2.8	23
139	Cephalometric features in isolated growth hormone deficiency. Angle Orthodontist, 2011, 81, 578-583.	2.4	25
140	Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naÃ¯ve patients with acromegaly. Pituitary, 2010, 13, 115-122.	2.9	61
141	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323
142	Adipokine Profile and Urinary Albumin Excretion in Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 693-698.	3.6	34
143	Longevity in Untreated Congenital Growth Hormone Deficiency Due to a Homozygous Mutation in the GHRH Receptor Gene. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 714-721.	3.6	92
144	Mutation Analysis of the Muscarinic Cholinergic Receptor Genes in Isolated Growth Hormone Deficiency Type IB. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2565-2570.	3.6	7

#	Article	IF	Citations
145	Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2428-2436.	3.6	104
146	Chapter 3 Diseases Associated with Growth Hormoneâ€Releasing Hormone Receptor (GHRHR) Mutations. Progress in Molecular Biology and Translational Science, 2009, 88, 57-84.	1.7	24
147	Partial Rescue of Growth Failure in Growth Hormone (GH)-Deficient Mice by a Single Injection of a Double-Stranded Adeno-Associated Viral Vector Expressing the GH Gene Driven by a Muscle-Specific Regulatory Cassette. Human Gene Therapy, 2009, 20, 759-766.	2.7	26
148	Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency. Psychoneuroendocrinology, 2009, 34, 894-900.	2.7	22
149	Pituitary tumors. Current Treatment Options in Neurology, 2009, 11, 287-296.	1.8	6
150	Consequences of lifetime isolated growth hormone (GH) deficiency and effects of shortâ€term GH treatment on bone in adults with a mutation in the GHRHâ€receptor gene. Clinical Endocrinology, 2009, 70, 35-40.	2.4	27
151	Laryngeal and vocal evaluation in untreated growth hormone deficient adults. Otolaryngology - Head and Neck Surgery, 2009, 140, 37-42.	1.9	22
152	Ectopic Cushing's syndrome: some facts. Indian Journal of Medical Research, 2009, 129, 4-6.	1.0	26
153	Clinical management of growth hormone therapy in adults. Managed Care, 2009, 18, 10-6.	0.3	1
154	Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clinical Endocrinology, 2008, 69, 153-158.	2.4	41
155	Climacteric in untreated isolated growth hormone deficiency. Menopause, 2008, 15, 743-747.	2.0	18
156	Heterozygosity for a Mutation in the Growth Hormone-Releasing Hormone Receptor Gene Does Not Influence Adult Stature, But Affects Body Composition. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2353-2357.	3.6	29
157	Congenital Growth Hormone (GH) Deficiency and Atherosclerosis: Effects of GH Replacement in GH-Naive Adults. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4664-4670.	3.6	57
158	Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clinical Endocrinology, 2007, 66, 070115055241013.	2.4	18
159	Vitamin A deficiency does not influence longitudinal growth in mice. Nutrition, 2007, 23, 483-488.	2.4	11
160	A new mutation in the growth hormone-releasing hormone receptor gene in two Israeli Arab families. Journal of Endocrinological Investigation, 2006, 29, 122-130.	3.3	21
161	GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. Journal of Endocrinological Investigation, 2006, 29, 805-808.	3.3	15
162	Cushingâ€™s Syndrome Attributable to Ectopic Secretion of Corticotropin in A Patient with Two Neuroendocrine Tumors. Endocrine Practice, 2006, 12, 656-659.	2.1	8

#	Article	IF	Citations
163	Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2093-2099.	3.6	76
164	Thyroid Morphology and Function in Adults with Untreated Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 860-864.	3.6	28
165	Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1290-E1294.	3.5	12
166	Autosomal-Dominant Isolated Growth Hormone Deficiency (IGHD Type II) with Normal GH-1 Gene. Hormone Research in Paediatrics, 2006, 65, 76-82.	1.8	7
167	Influence of Estrogen Administration on the Growth Response to Growth Hormone (GH) in GH-Deficient Mice. Experimental Biology and Medicine, 2005, 230, 715-720.	2.4	7
168	Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E762-E767.	3.5	18
169	Partial Reversibility of Growth Hormone (GH) Deficiency in the GH-Releasing Hormone (GHRH) Knockout Mouse by Postnatal Treatment with a GHRH Analog. Endocrinology, 2005, 146, 1506-1513.	2.8	24
170	Naturally-occurring missense mutations in the human growth hormone-releasing hormone receptor alter ligand binding. Journal of Endocrinology, 2005, 186, 515-521.	2.6	22
171	Adrenal Insufficiency. JAMA - Journal of the American Medical Association, 2005, 294, 2481.	7.4	66
172	Effects of Combined Long-Term Treatment with a Growth Hormone-Releasing Hormone Analogue and a Growth Hormone Secretagogue in the Growth Hormone-Releasing Hormone Knock Out Mouse. Neuroendocrinology, 2005, 82, 198-207.	2.5	14
173	Effects of recombinant mouse growth hormone treatment on growth and body composition in GHRH knock out mice. Growth Hormone and IGF Research, 2005, 15, 275-282.	1.1	34
174	Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically Ill Surgical Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 2471-2476.	3.2	24
175	A Mouse with Targeted Ablation of the Growth Hormone-Releasing Hormone Gene: A New Model of Isolated Growth Hormone Deficiency. Endocrinology, 2004, 145, 4134-4143.	2.8	117
176	Phenotypic Analysis and Growth Response to Different Growth Hormone Treatment Schedules in Two Siblings with an Inactivating Mutation in the Growth Hormone-Releasing Hormone Receptor Gene. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 793-800.	0.9	2
177	Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene. Vitamins and Hormones, 2004, 69, 209-220.	1.7	24
178	Variability in anterior pituitary size within members of a family with GH deficiency due to a new splice mutation in the GHRH receptor gene. Clinical Endocrinology, 2004, 60, 470-475.	2.4	43
179	Growth Hormone and IGF-1. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 15-23.	5.7	25
180	Metastatic renal cell carcinoma to the pituitary presenting with hyperprolactinemia. Journal of Endocrinological Investigation, 2004, 27, 471-474.	3.3	19

#	Article	IF	Citations
181	Magnetic resonance imaging study of pituitary morphology in subjects homozygous and heterozygous for a null mutation of the GHRH receptor gene. European Journal of Endocrinology, 2003, 148, 427-432.	3.7	46
182	A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. European Journal of Endocrinology, 2003, 148, 25-30.	3.7	55
183	Growth Hormone-Releasing Hormone Receptor Mutations in Familial Growth Hormone Deficiency. , 2003, 13, 422-427.		4
184	Detection of a recurring mutation in the human growth hormone-releasing hormone receptor gene. Clinical Endocrinology, 2002, 57, 77-80.	2.4	31
185	Familial Isolated Growth Hormone Deficiency Is Associated with Increased Systolic Blood Pressure, Central Obesity, and Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2018-2023.	3.6	94
186	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site. Molecular Endocrinology, 2002, 16, 450-458.	3.7	73
187	Serum GH response to pharmacological stimuli and physical exercise in two siblings with two new inactivating mutations in the GH-releasing hormone receptor gene. European Journal of Endocrinology, 2002, 147, 591-596.	3.7	34
188	Hypothalamic/pituitary function and dysfunction. , 2002, , 853-870.		0
189	Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Gravesâ€™ disease. Journal of Endocrinological Investigation, 2002, 25, 639-642.	3.3	20
190	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site. Molecular Endocrinology, 2002, 16, 450-458.	3.7	22
191	Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clinical Endocrinology, 2001, 54, 301-307.	2.4	26
192	Isolated growth hormone (GH) deficiency due to compound heterozygosity for two new mutations in the GHâ€releasing hormone receptor gene. Clinical Endocrinology, 2001, 54, 681-687.	2.4	46
193	Study of the Multiple Endocrine Neoplasia Type 1, Growth Hormone-Releasing Hormone Receptor, GsÎ±, and Gi2Î± Genes in Isolated Familial Acromegaly1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 542-544.	3.6	26
194	Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3279-3283.	3.6	50
195	Three New Mutations in the Gene for the Growth Hormone (GH)-Releasing Hormone Receptor in Familial Isolated GH Deficiency Type IB1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 273-279.	3.6	92
196	Three New Mutations in the Gene for the Growth Hormone (GH)-Releasing Hormone Receptor in Familial Isolated GH Deficiency Type IB. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 273-279.	3.6	78
197	Familial growth hormone deficiency with mutated GHRH receptor gene: clinical and hormonal findings in homozygous and heterozygous individuals from Itabaianinha. European Journal of Endocrinology, 2000, 142, 557-563.	3.7	22
198	Effect of Severe Growth Hormone (GH) Deficiency due to a Mutation in the GH-Releasing Hormone Receptor on Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins, and Ternary Complex Formation Throughout Life1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4118-4126.	3.6	81

#	Article	IF	Citations
199	Familial Dwarfism due to a Novel Mutation of the Growth Hormone-Releasing Hormone Receptor Gene¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 917-923.	3.6	188
200	Familial Dwarfism due to a Novel Mutation of the Growth Hormone-Releasing Hormone Receptor Gene. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 917-923.	3.6	173